Novartis and its alpelisib will help with very rare diseases with malformations and excessive tissue growth.
Novartis
Posted inNew Drugs, Regulatory
Vabysmo: New Drug for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Faricimab by Roche is a strong competitor to Eylea.
Posted inNew Drugs, Regulatory
Susvimo: Pioneering Implant for Treating Wet Age-Related Macular Degeneration
Roche offered a convenient replacement for the traditional Lucentis.
Posted inClinical Trials, In the Pipeline, Neuroscience
Treating Parkinson’s Disease: Betting on Alpha-Synuclein
The pharmaceutical industry continues to fight hard against the devastating neurodegenerative disease.
Posted inAutoimmune Diseases, Clinical Trials, Neuroscience
Even Severe Multiple Sclerosis Can Be Cured
Atara Biotherapeutics and its awesome T-cell therapy against Epstein–Barr virus can really cure progressive forms of multiple sclerosis.
Posted inClinical Trials, COVID-19, Infections
Ensovibep: Drug for All Variants of Coronavirus Including Omicron
Molecular Partners and Novartis believe in the success of DARPins.
Posted inNeuroscience, Pharma & Biotech, Rare/Orphan Diseases
Biogen to Develop Updated Version of Spinraza
Nusinersen for the treatment of spinal muscular atrophy will get a follow-up.